The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn’’s disease

Author： Mascheretti Silvia   Schreiber Stefan  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.5, Iss.5, 2004-09, pp. : 479-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Anti-TNF agents in Crohn’s disease

By Assche G.V.   Rutgeerts P.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 103-111

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease

By Shetty A.   Forbes A.  

American Journal of PharmacoGenomics, Vol. 2, Iss. 4, 2002-01 ,pp. : 215-221

Adis International

Access to resources Recommend Favorite

Efficacy of Anti-TNF in Crohn's Disease: How Does it Work?

By  

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 138-142

Bentham Science Publishers

Access to resources Recommend Favorite

Anti - TNF Therapy for Crohn's Disease

By  

Current Pharmaceutical Design, Vol. 9, Iss. 4, 2003-02 ,pp. : 289-294

Bentham Science Publishers

Access to resources Recommend Favorite

Therapy of Crohn’s disease in childhood

By Beattie R Mark   Bremner A Ronald F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 809-825

Informa Healthcare

Access to resources Recommend Favorite